EL7.AI
Mergers & AcquisitionsMedium•16 November 2026•
4 min read

Johnson & Johnson Looks to Acquire Ollin for Up to $3.4 Billion

Key Facts

1Johnson & Johnson is looking to acquire Ollin for up to $3.4 billion, according to a Reuters report citing the Financial Times published on November 15, 2026.
2Ollin announced a $330 million Series B financing round on June 24, 2026.
3The randomized JADE comparison study included 164 patients.
4Ollin said global Phase 3 trials of OLN324 are being launched in the fourth quarter of 2026.

Reuters, citing the Financial Times, reported on November 15, 2026, that Johnson & Johnson is looking to acquire Ollin Biosciences for up to $3.4 billion. The report presents the deal value as a potential ceiling, not a confirmed final price. The acquisition remains under discussion, as the published report did not announce a definitive agreement. The proposed deal concerns a company developing treatments for eye diseases, led by a program preparing to advance to Phase 3 trials. That means the reported value is tied to a portfolio still in clinical development, not a commercially approved drug.

Ollin announced on June 24, 2026, that it had closed a $330 million Series B financing round to support development of its programs. The company said the round exceeded its target and that proceeds would fund development of its lead program, OLN324. Ollin plans to test the drug in global Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. The program targets two diseases affecting the retina, and the drug is a bispecific antibody targeting the VEGF and Ang2 pathways. The financing round provides an indication of the resources the company said it had earmarked for those trials before the report of a potential deal emerged.

Ollin based its case for the program on the randomized JADE study, which included 164 patients and compared OLN324 with faricimab, marketed as Vabysmo. The company said the drug delivered faster and greater improvements in retinal anatomy than faricimab in patients with diabetic macular edema and wet age-related macular degeneration. It also said vision gains were numerically higher in both studies. These results remain part of the data the company announced from a proof-of-concept study, not Phase 3 trial results. The reported clinical comparison forms the backdrop to the company's decision to advance the program, with Phase 3 the next testing step.

In preliminary results for the JADE study announced in January 2026, Ollin said nearly 90% of patients with diabetic macular edema who received a 4 mg dose of OLN324 showed no signs of disease at week 12, compared with 57% of those who received faricimab. The company also said improvement in retinal dryness in the OLN324 group was about 75% greater than the comparator at week one and about 50% greater at week 12. These percentages were published as results reported by the company from the JADE study. In its June announcement, Ollin described the improvement in retinal anatomy as faster and greater, and said vision gains were numerically higher in both studies. These figures provide additional context for the comparison the company cited in advancing OLN324 to the next stage of development.

Ollin began operations in September 2025 with $100 million in seed funding, then announced its $330 million Series B round in June 2026. Its portfolio also includes OLN102, a program for thyroid eye disease and Graves' disease being developed in collaboration with VelaVigo. At the company's launch, it said the program was expected to enter clinical development in 2026. That puts OLN102 at an earlier stage than OLN324, which has moved to planning for global Phase 3 trials. In January, Ollin estimated the global market for retinal-disease treatments at about $15 billion and linked that estimate to OLN324's potential; the estimate came from the company.

On the regulatory front, Ollin said it had completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration and received scientific advice from the European Medicines Agency on its Phase 3 program. In its June announcement, the company planned to begin global trials in the second half of 2026. It then said in a September update that global Phase 3 trials in diabetic macular edema and wet age-related macular degeneration were being launched in the fourth quarter of 2026. The September update provides a more specific timeline than the plan announced in June. The report published on November 15 did not include further details on the terms of the potential deal or its completion timeline.

Open on chart